BioLineRx Statistics
Total Valuation
BioLineRx has a market cap or net worth of $11.24 million. The enterprise value is $8.99 million.
| Market Cap | 11.24M |
| Enterprise Value | 8.99M |
Important Dates
The last earnings date was Monday, August 31, 2026, before market open.
| Earnings Date | Aug 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioLineRx has 2.62 billion shares outstanding. The number of shares has increased by 49.35% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 2.62B |
| Shares Change (YoY) | +49.35% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 0.39% |
| Owned by Institutions (%) | 4.39% |
| Float | 2.46B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.08 |
| Forward PS | 6.20 |
| PB Ratio | 0.68 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.20, with a Debt / Equity ratio of 0.48.
| Current Ratio | 1.20 |
| Quick Ratio | 1.01 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.01 |
Financial Efficiency
Return on equity (ROE) is -55.27% and return on invested capital (ROIC) is -26.58%.
| Return on Equity (ROE) | -55.27% |
| Return on Assets (ROA) | -19.82% |
| Return on Invested Capital (ROIC) | -26.58% |
| Return on Capital Employed (ROCE) | -61.46% |
| Weighted Average Cost of Capital (WACC) | 8.90% |
| Revenue Per Employee | $58,000 |
| Profits Per Employee | -$291,208 |
| Employee Count | 24 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 0.11 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.86% in the last 52 weeks. The beta is 0.70, so BioLineRx's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -33.86% |
| 50-Day Moving Average | 2.75 |
| 200-Day Moving Average | 2.86 |
| Relative Strength Index (RSI) | 41.28 |
| Average Volume (20 Days) | 27,696 |
Short Selling Information
The latest short interest is 135,948, so 2.81% of the outstanding shares have been sold short.
| Short Interest | 135,948 |
| Short Previous Month | 134,579 |
| Short % of Shares Out | 2.81% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.14 |
Income Statement
In the last 12 months, BioLineRx had revenue of $1.39 million and -$6.99 million in losses. Loss per share was -$0.00.
| Revenue | 1.39M |
| Gross Profit | 1.11M |
| Operating Income | -12.17M |
| Pretax Income | -10.14M |
| Net Income | -6.99M |
| EBITDA | -12.12M |
| EBIT | -12.17M |
| Loss Per Share | -$0.00 |
Balance Sheet
The company has $13.08 million in cash and $7.94 million in debt, with a net cash position of $5.14 million or $0.00 per share.
| Cash & Cash Equivalents | 13.08M |
| Total Debt | 7.94M |
| Net Cash | 5.14M |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | 16.62M |
| Book Value Per Share | 0.01 |
| Working Capital | 2.67M |
Cash Flow
In the last 12 months, operating cash flow was -$10.80 million and capital expenditures -$25,000, giving a free cash flow of -$10.83 million.
| Operating Cash Flow | -10.80M |
| Capital Expenditures | -25,000 |
| Depreciation & Amortization | 52,000 |
| Net Borrowing | -4.87M |
| Free Cash Flow | -10.83M |
| FCF Per Share | -$0.00 |
Margins
| Gross Margin | 80.03% |
| Operating Margin | -874.28% |
| Pretax Margin | -728.45% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioLineRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -49.35% |
| Shareholder Yield | -49.35% |
| Earnings Yield | -62.17% |
| FCF Yield | -96.32% |
Analyst Forecast
The average price target for BioLineRx is $22.00, which is 784.60% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $22.00 |
| Price Target Difference | 784.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (3Y) | 88.01% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 30, 2025. It was a reverse split with a ratio of 1:40.
| Last Split Date | Jan 30, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
BioLineRx has an Altman Z-Score of -17.51 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -17.51 |
| Piotroski F-Score | 2 |